AVONEX SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

INTERFERON BETA-1A

Beschikbaar vanaf:

BIOGEN CANADA INC

ATC-code:

L03AB07

INN (Algemene Internationale Benaming):

INTERFERON BETA-1A

Dosering:

30MCG

farmaceutische vorm:

SOLUTION

Samenstelling:

INTERFERON BETA-1A 30MCG

Toedieningsweg:

INTRAMUSCULAR

Eenheden in pakket:

0.5ML

Prescription-type:

Prescription

Therapeutisch gebied:

Immunomodulatory Agents

Product samenvatting:

Active ingredient group (AIG) number: 0131806004; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2005-07-18

Productkenmerken

_AVONEX_
_TM_
_ (interferon beta-1a) _
_Page 1 of 46 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AVONEX
TM
Interferon beta-1a
Liquid for injection, 30 µg, Intramuscular
Immunomodulator
Biogen Canada Inc.
3250 Bloor Street West, East Tower, Suite 1200
Toronto, ON
M8X 2X9
Date of Initial Authorization:
April 06, 1998
Date of Revision:
August 15, 2022
Submission Control Number: 262774
© Biogen [1998]. All rights reserved.
_ _
_ _
_AVONEX_
_TM_
_ (interferon beta-1a) _
_Page 2 of 46_
RECENT MAJOR LABEL CHANGES
[Section number and heading], [Subsection number and heading]
[MM/YYYY]
[Section number and heading], [Subsection number and heading]
[MM/YYYY]
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update entire
table”, click OK.]
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment...